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Abstract
Purpose Busulfan (BU) used as cytoreductive conditioning
prior to hematopoietic stem cell transplantation (HSCT) is
available as intravenous (IV) and oral (O) preparation. IV-
BU has clinical advantages associated with relevant incremen-
tal costs. The aim was to determine the economic impact of
IV-BU versus O-BU in adult HSCT recipients from a German
health care providers’ perspective.
Methods A budget-impact model (BIM) including costs and
risks for oral mucositis (OM), infection with OM, and hepatic
sinusoidal obstruction syndrome (SOS) was developed. Mod-
el inputs are literature data comparing clinical effects of IV-
BU versus O-BU and German cost data (conditioning therapy,
treatment of OM, infections, SOS without/with multiorgan
failure) from literature and tariff lists.
Results Base case calculations resulted the following: total
costs of adverse events were €86,434 with O-BU and €44,
376 with IV-BU for ten patients each. Considering costs of
adverse events and drugs, about €5840 for ten patients receiv-
ing IV-BU are saved. Sensitivity analyses were conducted in
several ways. Cost savings range between €4910 and €12,640
per ten patients for all adverse events and €2070 or €1140 per
ten patients considering SOS only. Drug treatment of SOS and
treatment of multiorgan failure during severe SOS are major
cost drivers. Worst case scenario calculations (assuming
−25 % risk of all adverse events for O-BU and +25 % for
IV-BU) yield up to €27,570 per ten patients with IV-BU.
Conclusions Considering costs of adverse events and drugs,
IV-BU is the dominant alternative from a German providers’
perspective. For more comprehensive economic evaluations,
additional epidemiological data, evidence on clinical out-
comes, patient-reported outcomes, and treatment patterns are
needed.
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Introduction
European data from 2001 to 2011 for hematopoietic stem cell
transplantation (HSCT) show that the number of allogeneic
HSCT doubled and the number of autologous HSCT in-
creased by 32 %, with an ongoing constant increase of about
1100 autologous HSCT per year since 2001 [1]. In Germany,
similar increases were observed, in allogeneic HSCT 107 %
and in autologous HSCT 37.9 % from 2001 to 2011 (first
transplantations only) [2]. In the course of this development,
pre-transplant regimens for both myelogenous and lymphoid
malignancies are continuously refined with the aim to reduce
toxicity and to improve survival [3–5]. This process resulted
also in a continuous replacement of total body irradiation dur-
ing conditioning therapy for HSCT by the bifunctional DNA
alkylating myelotoxic agent busulfan (BU) [4, 6, 5]. The
availability of the intravenous (IV) formulation of BU plays
an important role in the development of optimized treatment
plans [4–6, 3].
Oral intake of BU is problematic due to the large number of
tablets, which are required to achieve recommended BU doses
[7]. Oral BU intake causes severe irritation of the gastric
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mucosa accompanied by nausea and vomiting. Intestinal ab-
sorption of the drug is highly variable, and bioavailability is
largely unpredictable. Wide inter- and intra-patient variability
in BU pharmacokinetics is therefore a concern [5, 7]. The
therapeutic range of BU is narrow, and the total exposure to
BU seems to be critical for graft rejection and survival [5, 6,
3]. Oral mucositis (OM) and its consequences like severe pain,
problems of food intake, and rising risk of infection are ob-
served more frequently with the oral preparation of BU (O-
BU). The life-threatening complication of hepatic sinusoidal
obstruction syndrome (SOS) is a major complication of BU.
In clinical trials, it could be demonstrated that these adverse
events are reduced by use of the IV formulation [8–14].
The advantageous IV formulation of BU is associated with
incremental costs compared to O-BU. In Germany, an extra
budget, a so-called “Zusatzentgelt” ZE 79, is paid for the use
of IV-BU for HSCT recipients below the age of 15 years [15].
So far, IV-BU administration in adult patients is not covered
by a “Zusatzentgelt.” Additional costs associated with IV-BU
have to be covered by budget reimbursed through the specific
diagnosis-related groups (DRG). In 2012, 767 adult German
patients, 12.3 % of all HSCT, received BU for conditioning
prior to HSCT. Replacing O-BU with IV-BU would result in
an increase of total drug costs by approximately € 2.5 to € 3
million. However, from an economic perspective, it might be
misleading to consider isolated drug costs only. The impact of
total cost in comparison to the previous standard of care has to
be evaluated to determine the economic value. New therapies,
which are expensive, might be adopted, because they result in
essentially the same net total costs as the comparator due to a
reduction in costs for the treatment of adverse events. Budget-
impact models (BIMs) can be used to calculate “the net cu-
mulative cost of treatment with a particular therapy for a given
number of patients in a specific population” [16, 17]. BIMs
might give advice to the provider during decision making.
In the following, the development of a BIM is described,
analyzing net cumulative costs in adult HSCT recipients from
a German providers’ perspective comparing the IV formula-
tion of BU to the oral preparation.
Methods
Budget-impact model (BIM)
Model calculations are recommended to be used when the
number of data regarding treatment outcomes and treatment
patterns is limited. A decision tree model was developed with
Microsoft Excel 2010® to evaluate the budget impact of IV-
BU versus O-BU during conditioning for HSCT from a Ger-
man health care providers’ perspective. Drug costs, as well as
frequency and treatment costs of drug-related side effects and
adverse reactions, were considered (Fig. 1).
Model input
PubMED was searched for data comparing IV-BU versus O-
BU regarding risks for OM, infection with OM and SOS with
or without multiorgan failure (MOF). The following searches
were conducted: (“Busulfan”[Mesh]) and “Administration,
In t ravenous” [Mesh] ; (“Economics” [Mesh] ) and
“Stomat i t i s” [Mesh] ; (“Hepa t i c Veno-Occ lus ive
Disease”[Mesh]) and “Busulfan”[Mesh]; “Busulfan”[Mesh]
review, las t 10 years ; “Hepat ic Veno-Occlus ive
Disease”[Mesh] review, last 10 years. In addition, free search
terms, e.g., “oral mucositis” and “intravenous busulfan” were
applied. Citations of identified journal articles were searched
for further relevant publications. Desktop researches were
conducted. The model input consists of event rates and cost
data. Event rates for the base case and a short characterization
of the study populations are given in Table 1 [10, 11, 13, 14,
18, 19]. Mild SOSwas not considered. Reliable treatment cost
data and event rates are lacking for mild SOS due to generally
spontaneous cessation of the disease. German cost data shown
in Table 2 were taken from literature [20–25] and tariff lists,
except for cost of OM grade 1–2. Due to a lack of published
cost data, average costs of OM grade 1–2 were determined
based on resource use (time of physicians and nurses, rinsing
solutions, local anesthetics, antimycotics, morphine gel) esti-
mated by clinical experts and trained nurses.
Assumption
Due to a lack of German cost data on SOS or length of hospital
stay with SOS in Germany, it was assumed that cost of SOS is
represented by treatment with defibrotide as a major cost com-
ponent. Defibrotide is recommended for treatment of SOS
[26].
Base case
Calculations in the model were started with a base case. Adult
patient weighed 70 kg was conditioned prior to HSCT with
1.0 mg/kg O-BU or 0.8 mg/kg IV-BU four times daily for
4 days. The event rates of OM and SOS for the base case were
taken from the studies of Sobecks et al. [14] and Lee et al. [13]
(Table 1). Both are more recent studies with large study pop-
ulations concerning allogeneic HSCT and conditioning with
BU and cyclophosphamide.
Sensitivity analyses
Sensitivity analyses were conducted in several ways. (1)
Event rates of OM from the study of Ferrara et al. [10] and
event rates of SOS from the study of Kashyap et al. [11] were
inserted in the model (Table 3). (2) Calculations were conduct-
ed considering SOS only without costs for OM and infection
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with OM. (3) Minus and plus 25 % of risks of all adverse
events for O-BU and IV-BU were applied. (4) A worst case
scenario was calculated assuming minus 25 % of risks of all
adverse events for O-BU and plus 25 % for IV-BU [27].
Model output
Model output was expressed as total costs of adverse events
with O-BU, total costs of adverse events with IV-BU, total
costs of adverse events with O-BU plus drug costs of O-BU,
and total costs of adverse events with IV-BU plus drug costs of
IV-BU. Results were presented as follows: cost savings or
additional costs with IV-BU for ten patients; total costs for
groups of ten patients receiving O-BU or IV-BU, respectively.
In worst case scenarios assuming minus 25 % of risks of all
adverse events for O-BU and plus 25% for IV-BU, potentially
arising additional costs per ten patients with IV-BU were cal-
culated. All calculations were done using the event rates from
the different studies available. All adverse events were
considered, as well as drug costs for O-BU and IV-BU, if
not otherwise stated.
Number needed to treat
The number needed to treat (NNT) to prevent one additional
severe SOS was calculated using the base case event rates
from the study of Lee et al. (Table 1) [13]. A range was given:
lower border is a high hypothetical case of occurrence of SOS
with ten times higher event rates; upper border is a low hypo-
thetical case of occurrence of SOS with ten times lower event
rates [28].
Results
Drug costs considering ten patients for conditioning with O-
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Fig. 1 Decision tree. HSCT
hematopoietic stem cell
transplantation, BU busulfan, IV
intravenous, O oral, OM oral
mucositis, SOS hepatic sinusoidal
obstruction syndrome, MOF
multiorgan failure
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Results for base case calculations and sensitivity analyses
are displayed in Fig. 2. All calculations ended up in cost sav-
ings with IV-BU.
Considering SOS only as a relevant adverse event and
disregarding OM and infection with OM, cost savings in the
model are approximately €2070 per ten patients applying the
data of Lee et al. [13] and €1140 per ten patients with the data
of Kashyap et al. [11].
In the base case, total costs of adverse events were €86,434
with O-BU and €44,376 with IV-BU for ten patients each.
Total costs of adverse events with O-BU plus drug costs of
O-BUwere €99,594 and with IV-BU plus drug costs of IV-BU
€93,755 for ten patients each (Fig. 3a, base case: event rates
from Sobecks/Elting/Lee et al.). Cost of adverse events plus
drug costs of BU using the different study data available are
shown in Fig. 3b–d. The development of total costs in sensi-
tivity analyses assuming either minus 25 % (minimum) or
plus 25 % (maximum) of risks of all adverse events for O-
BU and IV-BU for the base case and all different study data
available is included in Fig. 3a–d.
Calculating worst case scenarios assuming minus 25 % of
risks of all adverse events for O-BU and plus 25 % for IV-BU
results in additional costs with IV-BU of €27,570 per ten pa-
tients with the data of Sobecks et al. [14] and Lee et al. [13]
(base case), €25,040 per ten patients with the data of Sobecks
et al. [14] and Kashyap et al. [11], €24,970 per ten patients
with the data of Ferrara et al. [10] and Lee et al. [13], €22,440
per ten patients with the data of Ferrara et al. [10] and Kashyap
et al. [11]. Omitting the costs for OM and infection with OM
in the worst case scenario leads to additional costs with IV-BU
of €23,070 per ten patients using the data of Lee et al. [13] for
SOS and of €22,830 per ten patients using the data of Kashyap
et al. [11] for SOS.
The average NNT results in 17 patients needed to treat to
prevent one case of severe SOS, with a range of 2 to 169
Table 1 Model input: event rates base case
Parameter Event rate [%] Study population Source
O-BU IV-BU
Risk of oral mucositis (OM)
Patients without OM 44.18 97.5 Allogeneic HSCT; conditioning: BU/cyclophosphamide;
93 patients O-BU compared to 42 patients IV-BU
Sobecks et al. (2012) [14]
Patients with OM Grade 1–2 31.4 0
Patients with OM Grade 3–4 24.42 2.5
Risk of documented infection with OM
Patients with infection without OM 18.12 599 Cancer patients with chemotherapy-induced
myelosuppression
Elting et al. (2003) [19]
Patients with infection with OM Grade 1–2 18.98
Patients with infection with OM Grade 3–4 35.71
Risk of hepatic sinusoidal obstruction syndrome (SOS)
Patients with moderate SOS 16.67 14.55 Allogeneic HSCT; conditioning: BU/cyclophosphamide;
186 patients O-BU compared to 55 patients IV-BU
Lee et al. (2005) [13]
Patients with severe SOS 5.91 0
Patients with severe SOS with MOF 4.98 0
Frequency to develop fatal multiorgan
failure (MOF) with severe SOS
84.3 Meta-analysis of published studies from 1979
to October 2007
Coppell et al. (2010) [18]
Table 2 Model input: cost
Parameter Cost [€] Source
Drug costs
O-BU 1 mg 1.18 Wholesale price 2013
exclusive of VAT [25]
IV-BU 1 mg 5.51 Wholesale price 2013
exclusive of VAT [25]
Defibrotide 1 mg 0.82 German NUB
Antrag 2012/2013 [24]
Total costs for adverse events
OM Grade 1–2 50 Own estimation based on
clinical experts
OM Grade 3–4 312 Banz et al.(2011) [20]
Infection 7 093 Paessens et al. (2011) [22]
Moderate SOS 21 398 a
Severe SOS 35 663 a
Severe SOS with MOF 61 109 b
VAT value-added tax
a Costs of SOS were estimated calculating the costs of treatment with
defibrotide according to the German NUB Antrag (new examination
and treatment methods application) 2012/2013 assuming dosing accord-
ing to Richardson et al. [23, 24]. Average duration ofmoderate and severe
SOS (15 and 25 days, respectively) were taken from the study of Lee et al.
[13]
b Cost of MOFwas estimated by addition of German costs for fatal sepsis
to costs of severe SOS [21]
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patients using high and low hypothetical cases of occurrence
of SOS [28].
Discussion
This is the first economic assessment of IV-BU compared to
O-BU presented for Germany. Considering risks and treat-
ment costs for OM, infection with OM and SOS, as well as
drug costs, IV-BU is cost saving and therefore dominant com-
pared to O-BU. IV-BU remains the dominant alternative, even
if the study data used for the base case are replaced by other
available study data or if solely the adverse event SOS is
considered.
Two other economic models have been presented so far as
conference abstracts comparing costs arising with O-BU com-
pared to IV-BU taking only SOS into consideration. Based on
US costs for SOS [29], a French model calculated additional
costs of €1605.4 per patient with IV-BU [30]. A cost-
effectiveness analysis from Mexico demonstrated that IV-
BU was dominant over O-BU [31]. Taking different event
rates and different health care systems into consideration, a
comparison with these studies is limited.
In sensitivity analyses, changes in total cost of adverse
events calculating with plus and minus 25 % of all risks were
chosen for the following reasons: the historical nature of the
available study data leads to considerable uncertainties despite
a similar trend regarding the favorable results with IV-BU.
The cost components could not be based on up-to-date data
of treatment patterns and resource use and were estimated in a
most conservative way, e.g., not including costs of hospital
stay for SOS. Therefore, it did not seem adequate to analyze
the influence of individual parameters in this context of un-
certainties of event rates and cost components. Worst case
scenarios assuming minimal risks of adverse events for O-
BU (−25 %) and maximal risks of adverse events for IV-BU
(+25 %) result in additional costs for IV-BU amounting to a
maximum of 56 % of the drug costs using base case data.
These extra costs appear relatively modest in the context of
HSCT [32].
The average NNTwith IV-BU is 17 patients to prevent one
case of severe SOS. Regarding the total number of patients
Table 3 Model input: event rates sensitivity analyses
Parameter Event rate [%] Study population Source
O-BU IV-BU
Risk of oral mucositis (OM)
Patients without OM 7 72 Autologous HSCT; conditioning: BU/idarubicin;
30 patients O-BU compared to 25 patients IV-BU
Ferrara et al. (2009) [10]
Patients with OM Grade 1–2 13 16
Patients with OM Grade 3–4 80 12
Risk of hepatic sinusoidal obstruction syndrome (SOS)
Patients with moderate SOS 13.33 4.92 Allogeneic HSCT; conditioning: BU/cyclophosphamide;
30 patients O-BU compared to 61 patients IV-BU
Kashyap et al. (2002) [11]
Patients with severe SOS 6.67 3.28































base case sensitivity analyses on event rates
Fig. 2 Average cost savings per
ten patients with IV-BU. Average
cost savings per ten patients with
IV-BU are shown for the base
case. For the sensitivity analyses,
event rates of OM from the study
of Ferrara et al. [10] and event
rates of SOS from the study of
Kashyap et al. [11] were inserted
in the model. S = Sobecks et al.
[14], E = Elting et al. [19],
L = Lee et al. [13], K = Kashyap
et al. [11], F = Ferrara et al. [10]
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treated in Germany with BU for conditioning prior to HSCT,
potentially up to 45 patients are spared severe SOS. In view of
the considerable mortality of severe SOS after allogeneic
HSCT, IV-BU appears highly favorable [18].
If pharmacokinetic-directed high-dose BU is used, similar
results can be achieved with O-BU and IV-BU. However, the
data indicated a slightly improved 5-year overall survival with
IV-BU compared to O-BU [33]. A prospective cohort study
comparing IV-BU with total body irradiation (TBI) used for
conditioning prior to HSCT demonstrated non-inferiority of
IV-BU. Two-year probabilities of survival were improved
with IV-BU compared to TBI [4]. An earlier study comparing
O-BU with IV-BU during reduced intensity conditioning for
allogeneic HSCT found lower incidence of acute graft-versus-
host disease (GvHD) and early infectious complications lead-
ing to significantly improved overall survival with IV-BU
[34]. Further studies are required to understand the mecha-
nisms by which IV-BU-based regimens result in superior sur-
vival outcomes and to evaluate possible influences on GvHD.
Due to increasing rates of GvHD with increasing toxicity of
the regimens preceding allogeneic HSCT, the advantages of
IV-BU may be even more pronounced [35]. In contrast to a
cost-effectiveness analysis, a BIM does not consider differ-
ences in mortality rates of therapies, i.e., differences in life
years gained [32]. Improvements in quality of life, which are
achieved by less and less severe OM during treatment with IV-
BU compared to O-BU, are not reflected in the calculations.
There are some limitations concerning studies and cost data
inserted in the model. The data used for the model comparing
frequencies of adverse events with O-BU and IV-BU were
from four retrospective clinical studies [11, 13, 14, 19] and
one prospective and retrospective comparison [10] with obvi-
ously heterogenous patient populations. In one study, the
groups had variable use ofmethotrexate [14]; in another study,
patients with a different ethnic background as compared to
German patients were investigated [13], and another study
comprised autologous HSCT instead of allogeneic HSCT
and used an experimental drug combination of BU and
idarubicin [10]. The conclusions of the model had to be based
exclusively on literature historical data due to lack of up-to-
date evidence-based studies. Infection rates with OM were
derived from a study on chemotherapy-induced OM in cancer
patients, because comparative data on infections in patients
with or without OM after HSCTwere not available [19]. Cost
data for treatment of OM grade 3–4 and for treatment of in-
fection were both from publications on cancer patients receiv-
ing chemotherapy [20, 22]. Published data on treatment costs
of OM and infection of patients after allogeneic HSCT were
not available and might differ in patients after chemotherapy


































































































































Fig. 3 Sensitivity analyses:
minus and plus 25% of risks of all
adverse events for O-BU and IV-
BU. Total costs of adverse events
plus drug cost of BU are shown
for groups of ten patients each
with either O-BU or IV-BU.
Minus 25 % (minimum) and plus
25 % (maximum) of risks of all
adverse events for O-BU and IV-
BU were applied on the event
rates of all available studies on
OM, infection with OM, and SOS
[10, 11, 13, 14, 19]. S = Sobecks
et al. [14], E = Elting et al. [19],
L = Lee et al. [13], K = Kashyap
et al. [11], F = Ferrara et al. [10],
(min) = minimum, (max) =
maximum
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influence on length of hospital stay or readmission to the hos-
pital. Estimations had also to be made for German cost data on
SOS. Treatment costs of SOS were based on the assumption
that defibrotide is a major cost component. This is a simplifi-
cation of a probably much more complex issue. However
again, German cost data on SOS or length of hospital stay
with SOS in Germany were not available. Therefore, this es-
timation close to current clinical practice was chosen. Various
approaches in the sensitivity analyses were used to account for
these uncertainties. The applicability of this economic assess-
ment of IV-BU compared to O-BU from a German providers’
perspective to other countries is limited. The influence of IV-
BU on costs may produce variable results as a function of
differences in treatment patterns, costs, health care systems,
and the country-specific type of health economic evaluation.
However, the basic approach of our model calculations can be
transferred to other countries using country-specific costs for
treatment of adverse events and, if available, up-to-date study
data comparing IV-BU with O-BU.
Conclusions
The presented budget-impact calculations (IV-BU compared to
O-BU) from a German health care providers’ perspective show
cost savings in overall costs of HSCT. Sensitivity analyses result
in moderate cost increase for IV-BUwhen calculating worst case
scenarios. Based onmodel calculations, the use of IV-BU in adult
patients undergoing HSCT seems to be reasonable. Contempo-
rary real-life data on frequencies of OM and SOS in the course of
HSCTwith IV-BU compared to O-BU, up-to-date treatment pat-
terns for OM and SOS, as well as resource use and costs of OM,
SOS, and HSCT are needed to allow for further analyses.
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